Annual Report 2018

Section of Knowledge Integration

Shinji Kohsaka, Taro Shibata, Yasushi Goto, Kazuya Tsuchihara, Hiromi Takawashi, Risa Miyagawa

Introduction

Development of Cancer Knowledge Data Base
  CKDB (Cancer Knowledge Data Base) was developed to improve the quality of cancer genome testing. Moreover, a curator team consisting of about 25 clinical oncologists and bioinformaticians was organized to maintain the system, monthly updating data of clinical trials, medicines and maker evidence.

The Team and What We Do

 We provided expert panel C-CAT findings, a report summary of clinical trials, medicines and maker evidence to annotate clinical significance to variants found by cancer panel testing performed by clinical laboratories. We also established a management system to control the quality of C-CAT findings by standardizing the process of the review by expert reviewers, who are equivalent to M.D. or Ph.D.

Research activities

 CKDB was developed by collecting, standardizing and integrating the information of maker evidence, anti-cancer therapy and clinical trial. Using the CKDB, we constructed a system to generate C-CAT findings. CKDB-portal was also developed to search, inquire and curate the knowledge stored in CKDB.

Education

 Monthly curator meetings were held to educate the curators and maintain the quality of CKDB curation. Monthly expert reviewer meetings were held to educate the expert reviewers and standardize the review process of C-CAT findings.

Future prospects

 C-CAT findings support the expert panel with information on the newest evidence, anticancer therapies and clinical trials, and, as a result, the genome medicine will be uniformly and efficiently promoted. Furthermore, promotion of clinical trials will activate new drug development in Japan, lead to the discovery of evidence and contribute to great progress in cancer medicine (Figure 1).

Figure 1. Development of CKDB to improve the quality of genome medicine